Efficacy and Safety of ALT-801 in the Treatment of Obesity

Phase 2

Completed

• Conditions: Obesity/Overweight
• Interventions: Drug: ALT-801; Other: Placebo

• Registration Number: NCT05295875
• Lead Sponsor: Altimmune, Inc.

Brief Summary

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-02-07
• Study First Submitted QC: 2022-03-21
• Study First Posted: 2022-03-25
• Study Start: 2022-03-31
• Primary Completion: 2023-09-28
• Study Completion: 2023-09-28
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-27
• Last Update Posted: 2023-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 391

Inclusion Criteria

• Written informed consent signed prior to entry into the study
• Male or female age 18 to 75 years, inclusive
• Body mass index (BMI) ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 combined with at least one obesity-related comorbidity
• At least one unsuccessful weight loss attempt per investigator judgement
• Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study
• Female subjects of childbearing potential who are not pregnant or breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control

Exclusion Criteria

• Weight gain or loss > 5% in the 3 months prior to randomization or >10% in the 6 months prior to screening

• Diabetes and related conditions:

  1. History or clinical evidence of diabetes mellitus of any type, including Type 1, Type 2, or mature onset diabetes of the young (MODY)
  2. HbA1c > 6.5%, fasting glucose ≥ 126 mg/dL (6.9 mmol/L), and/or random glucose of ≥ 200 mg/dL (11.0mmol/L) at screening

• Obesity and related conditions:

  1. Obesity induced by known genetic causes or endocrine disorders (eg, Cushing Syndrome, inadequately treated hypothyroidism, defined as thyroid-stimulating hormone [TSH] > 6 mIU/L)
  2. History of bariatric surgery or other surgical treatment for obesity (eg, gastric banding, gastric bypass), or planned surgery or surgical treatment during the study. Liposuction and/or abdominoplasty performed >1 year before screening is allowed. Endoscopically placed intragastric balloons will be allowed if removed > 1 year before screening.

• Gastrointestinal conditions:

  1. History of acute or chronic pancreatitis within 1 year (365 days) before screening
  2. History of or acute significant gastrointestinal (GI) disorder (eg, peptic ulcers, severe gastroesophageal reflux disease [GERD],
  3. History of GI surgery, including cholecystectomy and antrectomy. Surgery for appendicitis and small bowel resection >20cm is acceptable.
  4. History of inflammatory bowel disease, celiac disease or any medical condition or surgery that could affect gastric emptying, stool frequency or stool consistency. (Irritable bowel syndrome is permitted provided that bowel frequency and consistency are normal off treatment.)

• Mental health conditions:

  1. Untreated depressive disorder, defined as a Patient Health Questionaire-9 (PHQ-9) score of ≥ 15 at screening
  2. Suicide ideation, defined as type 4 or 5 on the Columbia-Suicide Severity Rating Scale(C-SSRS) at screening, lifelong history of a suicide attempt, or suicidal behavior within 30 days before screening
  3. Other severe psychiatric disorder (eg, schizophrenia, bipolar disorder)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ALT-801 Dose Level 1	ALT-801	-
Placebo	Placebo	-
ALT-801 Dose Level 3	ALT-801	-
ALT-801 Dose Level 2	ALT-801	-

Primary Outcome Measures

Name	Time	Method
Relative change from baseline in body weight percentage	Baseline to Week 48

Secondary Outcome Measures

Name	Time	Method
Changes from baseline in Hemoglobin A1c	Baseline to Week 48
Change from baseline in proportion of patients using antihypertensive medications	Baseline to Week 48
Changes from baseline in: a) Systolic blood pressure, b) Diastolic blood pressure	Baseline to Week 48
Percent proportion of subjects with weight loss of greater than or equal to 5%, 10%, and 15%	Baseline to Week 48
The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)	Baseline to Week 48
Changes from baseline in Homeostatic Marker Assessment for Insulin Resistance (HOMA-IR)	Baseline to Week 48
Changes from baseline in Fasting Glucose	Baseline to Week 48
Change from baseline in lipids	Baseline to Week 48

Trial Locations

Locations (4)

Altimmune CTM; 🇺🇸 Saint George, Utah, United States

National Research Institute; 🇺🇸 Los Angeles, California, United States

Cornell University, Joan and Sanford Weill Medical College; 🇺🇸 New York, New York, United States

Midwest Institute for Clinical Research; 🇺🇸 Indianapolis, Indiana, United States